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  “[Restless legs syndrome] is quite a serious sleep 
disorder that affects a lot of people....Their sleep is 
disturbed and, unless they are really awake, they 
will not be aware of it” [1].
    L
ife can be hard. Sometimes you 
feel sad or distracted or anxious. 
Or maybe you feel a compelling 
urge to move your legs. But does that 
mean you are sick? Does it mean you 
need medication?
    Maybe, maybe not. For some people, 
symptoms are severe enough to be 
disabling. But for many others with 
milder problems, these “symptoms” 
are just the transient experiences of 
everyday life. Helping sick people get 
treatment is a good thing. Convincing 
healthy people that they are sick is 
not. Sick people stand to beneﬁ  t from 
treatment, but healthy people may only 
get hurt: they get labeled “sick,” may 
become anxious about their condition, 
and, if they are treated, may experience 
side effects that overwhelm any 
potential beneﬁ  t. 
    “Disease mongering” is the effort 
by pharmaceutical companies (or 
others with similar ﬁ  nancial interests) 
to enlarge the market for a treatment 
by convincing people that they are 
sick and need medical intervention 
[2]. Typically, the disease is vague, 
with nonspeciﬁ  c symptoms spanning 
a broad spectrum of severity—from 
everyday experiences many people 
would not even call “symptoms,” to 
profound suffering. The market for 
treatment gets enlarged in two ways: 
by narrowing the deﬁ  nition of health 
so normal experiences get labeled 
as pathologic, and by expanding the 
deﬁ  nition of disease to include earlier, 
milder, and presymptomatic forms 
(e.g., regarding a risk factor such as 
high cholesterol as a disease in itself). 
    Discussions about disease 
mongering usually focus on the role of 
pharmaceutical companies—how they 
promote disease and their products 
through “disease awareness” campaigns 
and direct-to-consumer drug 
advertising, and by funding disease 
advocacy groups. But diseases also get 
promoted in another way: through 
the news media. News reports are a 
major source of health information 
for people [3]. Unless journalists 
approach stories about new diseases 
skeptically and look out for disease 
mongering by the pharmaceutical 
industry, pharmaceutical consultants, 
and advocacy groups, journalists, too, 
may end up selling sickness. 
    The Case of Restless Legs 
Syndrome
    To get a sense of how the media works 
in the context of a major disease 
promotion effort, we examined news 
coverage of “restless legs” (see sidebar). 
In 2003, GlaxoSmithKline launched a 
campaign to promote awareness about 
restless legs syndrome, beginning with 
press releases about presentations at 
the American Academy of Neurology 
meeting describing the early trial 
results of using ropinirole (a drug 
previously approved for Parkinson 
disease) for the treatment of restless 
legs [6,7]. Two months later, 
GlaxoSmithKline issued a new press 
release entitled “New survey reveals 
common yet under recognized 
disorder—restless legs syndrome—is 
keeping Americans awake at night” 
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  What Is Restless Legs 
Syndrome?
    The diagnosis of restless legs 
syndrome requires the presence of the 
following four criteria [4]: 
    •  An urge to move the legs due to an 
unpleasant feeling in the legs.
    •  Onset or worsening of symptoms 
when at rest or not moving around 
frequently.
    •  Partial or complete relief by movement 
(e.g., walking) for as long as the 
movement continues.
    •  Symptoms that occur primarily at night 
and that can interfere with sleep or 
rest.
    The severity of disease is judged by 
the frequency of these symptoms, which 
can range from less than once a month 
to many times a day. Recommended 
treatments include stretching exercises 
and less caffeine for intermittent 
disease and various prescription drugs 
(e.g., benzodiazepines and dopamine 
agonists) for daily symptoms [5].  PLoS Medicine  |  www.plosmedicine.org 0453
about an internally funded and, at the 
time, unpublished study [8]. In 2005, 
the US Food and Drug Administration 
(FDA) approved ropinirole for the 
treatment of restless legs syndrome 
(the ﬁ  rst drug approved speciﬁ  cally 
for this indication). Since then, the 
restless legs campaign has developed 
into a multimillion dollar international 
effort to “push restless legs syndrome 
into the consciousness of doctors and 
consumers alike” [9].
    Newspaper Coverage of the 
Restless Legs Syndrome
    To identify media coverage related 
to this campaign over two years 
(November 2003–November 2005), 
we did full-text searches of “major 
newspapers” in Lexis-Nexis and 
ProQuest databases and found 187 
unique articles with the phrase “restless 
legs.” We excluded articles not about 
the syndrome (e.g., “Elvis’s restless 
legs”), nonnews stories (e.g., health 
advice columns, notices of restless legs 
health screenings/support groups), 
and articles with only passing mention 
of restless legs (most of these were 
about sleep disorders, another “new 
yet largely unrecognized problem”). 
We analyzed the remaining 33 articles 
(all focused on restless legs syndrome) 
using an explicit coding scheme 
organized around the key elements of 
disease mongering, as outlined in the 
ﬁ  rst column of Table 1: exaggerating 
the prevalence of the disease (e.g., 
uncritically accepting a broad 
prevalence estimate), encouraging 
more diagnosis (e.g., doctors fail to 
recognize it), and suggesting that 
all disease should be treated (e.g., 
overstating the beneﬁ  ts or minimizing 
the harms of treatment).
  Exaggerating  Disease  Prevalence 
    Figure 1 shows that the news articles 
often included elements exaggerating 
disease prevalence. Only one article 
questioned the disease deﬁ  nition at all 
(and portrayed the act of questioning 
the deﬁ  nition as insensitive: “[the 
patient] knows it can sound trivial. 
That’s one of the problems with restless 
legs. Radio show host Rush Limbaugh, 
for example, has mocked it as a 
pseudoillness” [10]). 
    Almost two-thirds of articles provided 
an estimate of disease prevalence (most 
commonly, statements such as “at least 
12 million Americans suffer from the 
syndrome” [11] or “[it] affects 1 in 10 
  Table 1.   Key Elements of Disease Mongering and How the Media Could Do Better   
Key Elements of Disease Mongering When the Media Can Get Co-opted Suggestions for Doing Better
Exaggerate the prevalence of disease
Create a broad disease deﬁ  nition based on 
vague and prevalent symptoms.
Uncritically accepts disease deﬁ  nition. Learn exact deﬁ  nition of disease and question whether it is appropriately 
speciﬁ  c. 
Publicize a large prevalence estimate. Uncritically repeats a broad prevalence estimate. Determine whether the prevalence estimate is credible: Are the “gold 
standard” diagnostic criteria being used as designed? Does the sample 
truly represent the general population? 
Blur the distinction between mild and severe 
disease.
Highlights the important physical, social, and 
emotional consequences of severe disease; only 
telling anecdotes of people with very severe 
disease.
Be clear about the spectrum of disease. When describing important 
consequences or personal anecdotes, provide the appropriate 
prevalence estimate by stating proportion with disease this severe. 
Encourage more diagnosis 
Highlight that doctors fail to recognize 
disease.
Quotes an “expert” about how doctors miss the 
diagnosis; provides anecdotes of people whose 
diagnoses were missed.
Acknowledge the problems of overdiagnosis (e.g., downside of labeling 
people with disease or medicalizing healthy people).
Encourage people to see themselves as sick.  Presents anecdotes or descriptions of people who 
are unaware that they are sick; encourages self-
diagnosis (e.g., symptom checklist).
Same as above.
Promote disease awareness (e.g., disease 
awareness week, screening clinics, support 
groups, disease foundations).
Publicizes disease awareness activities without 
noting industry involvement (e.g., “nonproﬁ  t” 
foundation).
Learn and state whether disease awareness activities are industry 
sponsored. 
Suggest that all disease should be treated
Exaggerate the beneﬁ  ts of the drug for 
everyone with disease.
Overstates the beneﬁ  t by providing only 
qualitative descriptions (e.g., only stating 
“signiﬁ  cant improvement” or telling stories of 
dramatic beneﬁ  t).
Objectively report beneﬁ  t by quantifying how well the drug works (e.g., 
present the proportion with clinically important symptom improvements 
in the drug and comparison group). Be clear about the populations 
studied (i.e., acknowledge that the beneﬁ  t is much smaller for people 
with mild disease). 
Overstates the beneﬁ  t by using miracle language 
to describe the beneﬁ  t. 
Avoid miracle language.
Overstates the beneﬁ  t by quoting a strong claim 
of beneﬁ  t from researchers with strong industry 
ties.
Learn and state industry ties of researchers who make strong claims 
about a drug’s beneﬁ  t.
Imply that there is no downside to 
treatment.
Minimizes the harms by not mentioning the 
possibility of them or by only telling stories of 
people who did not experience any harms.
Quantify side effects (e.g., present the proportion with side effects in the 
drug and comparison group).
Imply that long- term treatment is safe and 
effective.
Ignores concerns about duration of clinical trials 
(e.g., not mentioning length of follow-up).
Caution readers that although treatment is generally long term, the 
longest study was x weeks. So, the long-term beneﬁ  ts and harms are 
unknown.
 DOI:  10.1371/journal.pmed.0030170.t001 
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adults in the United States” [12]). No 
article questioned the validity of the 
prevalence estimates. In fact, there 
are reasons to believe the estimates 
overstate the prevalence of clinically 
meaningful disease. For example, the 
frequently cited 10% estimate came 
from a study that used a single question 
to identify restless legs syndrome rather 
than the four standard criteria [13]. 
The less stringent deﬁ  nition inﬂ  ates 
the estimate because people with 
other causes of leg symptoms (e.g., 
leg cramps or diabetic neuropathy) 
are counted incorrectly as having the 
syndrome. 
    In a recent large study, only 7% 
of respondents reported all four 
diagnostic criteria, and only 2.7% 
reported moderately or severely 
distressing symptoms two or more 
times per week (i.e., the group for 
whom medical treatment might be 
appropriate) [14]. Even the 2.7% 
estimate is probably too high, because 
of bias inherent in the study sample. 
The authors claimed an implausible 
98% response rate to their random-
digit dial survey (typical response rates 
are 50%–70% [15]). Most likely, the 
authors meant that 98% of individuals 
who agreed to participate completed 
the survey. But respondents agreeing 
to participate in a restless legs study 
are more likely to have leg-related 
symptoms than nonrespondents. 
    Nearly three-quarters of newspaper 
articles highlighted the potentially 
serious physical, social, and emotional 
consequences of restless legs: “…the 
condition sounds like a joke, but its 
consequences can be devastating. 
Driven to despair by years of sleepless 
nights, patients have become suicidal” 
[16]). While over 40% of the articles 
provided anecdotes about people with 
severe disease, no article provided 
anecdotes about people who did 
not ﬁ  nd their symptoms especially 
bothersome. 
  Encourage  More  Diagnosis
    The articles also reinforced the 
need for more diagnosis. About 
half reported that the syndrome 
is underdiagnosed by physicians 
(“…relatively few doctors know about 
restless legs. This is the most common 
disorder your doctor has never heard 
of” [17]) and underrecognized by 
patients (“…many people can suffer in 
silence for years before it is recognized” 
[18]). One-quarter of articles 
encouraged patient self-diagnosis and 
suggested people ask their doctor 
whether restless legs might explain 
various problems (including insomnia, 
daytime fatigue, attention deﬁ  cit 
disorder in children, and depression). 
One-ﬁ  fth of articles referred readers 
to the “nonproﬁ  t” Restless Legs 
Foundation for further information; 
none reported that the foundation is 
heavily subsidized by GlaxoSmithKline. 
No article acknowledged the possibility 
of overdiagnosis (the idea that some 
people will be diagnosed unnecessarily 
and take medication they do not really 
need). 
    Suggest That All Disease Should 
Be Treated
    About half the news stories mentioned 
the drug ropinirole by name. Only one 
story quantiﬁ  ed the drug’s beneﬁ  t. 
By contrast, about half the stories 
mentioning ropinirole included 
anecdotes about patients who took 
the drug (and in most cases noted 
substantial improvement). One-third 
of articles used “miracle language” 
to describe patient response to 
medication (e.g., “it has been a 
miracle drug for me” [19]). The actual 
beneﬁ  t of the drug is modest. The 
drug label reports that in a 12-week 
US clinical trial, restless legs symptom 
scores (measured on a 40-point scale) 
improved by 13.5 points for patients 
taking ropinirole compared with 9.8 
points for those taking placebo [20]. 
In more clinical terms, 73% taking 
ropinirole responded to the drug (i.e., 
restless legs scores improved by six 
points) compared with 57% taking 
placebo.
    The drug label [20] also notes that 
ropinirole has a number of side effects, 
including nausea (40% in ropinirole 
group versus 8% in placebo group) and 
dizziness (11% versus 5%, respectively). 
Somnolence and fatigue (ostensibly, 
the real target of the drug) were also 
higher in the ropinirole versus the 
placebo group (12% versus 6%; 8% 
versus 4%, respectively). Nonetheless, 
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  Figure 1.   Frequency of Key Elements of Disease Mongering in Newspaper Articles
      Top bar graph analyzes all articles about restless legs syndrome. Bottom bar graph analyzes the 
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only ﬁ  ve of the 15 articles mentioning 
ropinirole noted that it could have 
side effects and just one quantiﬁ  ed the 
chance of any side effect (“nausea was 
the most common side effect, reported 
in 38% of patients” [18]). Finally, 
only one news story noted that the 
ropinirole trials were “relatively short” 
in duration (the longest was 36 weeks), 
despite the fact that many people 
would use the drug for years or even a 
lifetime.
    Suggestions for How the Media 
Could Do Better
    Unfortunately, there is no obvious 
way to distinguish information from 
infomercial. In Table 1, we highlight 
clues that should alert journalists to 
the presence of disease mongering, 
and suggest some things they can do to 
expose these efforts.
    First, journalists should be very 
wary when confronted with a new 
or expanded disease affecting large 
numbers of people. If a disease is 
common and very bothersome, it is 
hard to believe that no one would have 
noticed it before. Prevalence estimates 
are easy to exaggerate by broadening 
the deﬁ  nition of disease. Journalists 
need to ask exactly how the disease is 
being deﬁ  ned, whether the diagnostic 
criteria were used appropriately, 
and whether the study sample truly 
represents the general population 
(e.g., patients at an insomnia clinic 
cannot be taken to represent the 
general public). 
    Journalists should also reﬂ  exively 
question whether more diagnosis is 
always a good thing. Simply labeling 
people with disease has negative 
consequences [21]. Similarly, 
journalists should question the 
assumption that treatment always 
makes sense. Medical treatments 
always involve trade-offs; people with 
mild symptoms have little to gain, and 
treatment may end up causing more 
harm than good. 
    Finally, instead of extreme, 
unrepresentative anecdotes about 
miracle cures, journalists should 
help readers understand how well 
the treatment works (e.g., what is the 
chance that I will feel better if I take 
the medicine versus if I do not?) and 
what problems it might cause (e.g., 
whether I might be trading less restless 
legs for daytime nausea, dizziness, and 
somnolence). 
  Conclusion
    The news coverage of restless legs 
syndrome is disturbing. It exaggerated 
the prevalence of disease and the need 
for treatment, and failed to consider 
the problems of overdiagnosis. In 
essence, the media seemed to have 
been co-opted into the disease-
mongering process. Although our 
review was limited to the coverage of a 
single disease promotion campaign, we 
think it is likely that our ﬁ  ndings would 
apply to others. It is easy to understand 
why the media would be attracted to 
disease promotion stories and why 
they would be covered uncritically. 
The stories are full of drama: a huge 
but unrecognized public health crisis, 
compelling personal anecdotes, 
uncaring or ignorant doctors, and 
miracle cures. 
    The problem lies in presenting 
just one side of the story. There 
may be no public health crisis, the 
compelling stories may not represent 
the typical experience of people with 
the condition, the doctors may be 
wise not to invoke a new diagnosis for 
vague symptoms that may have a more 
plausible explanation, the cures are far 
from miraculous, and healthy people 
may be getting hurt.
    We think the media could report 
medical news without reinforcing 
disease promotion efforts by 
approaching stories like “restless legs” 
with a greater degree of skepticism. 
After all, their job is to inform readers, 
not to make them sick.   
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